60 Degrees Pharmaceuticals (NASDAQ: SXTP) is a specialty pharmaceutical company focused on the development and commercialization of treatments for infectious diseases, with its primary commercial product being Arakoda (tafenoquine), a malaria prevention drug. Revenue comes from two streams: product sales, net of discounts and rebates, which totaled $1,005,471 in FY2025 versus $607,574 in FY2024, and research revenues of $403,624 in FY2025 versus $73,771 in FY2024, the latter driven in part by a USAMMDA government grant supporting Arakoda development and packaging. The company is pre-profitability, posting a net loss attributed to 60 Degrees Pharmaceuticals of $7,365,158 in FY2025 and $7,947,107 in FY2024. Operating expenses of $8,385,979 in FY2025 were dominated by general and administrative costs of $6,279,823 and research and development spending of $2,106,156. The company is incorporated in Delaware and has registered trademarks for Arakoda and Kodatef across multiple jurisdictions including Australia, Canada, China, the European Union, Israel, and New Zealand. Geoffrey Dow serves as President and Chief Executive Officer.

Revenue model

Two revenue streams: product revenues from sales of Arakoda (tafenoquine), net of discounts and rebates ($1,005,471 in FY2025), and research revenues including government grant funding ($403,624 in FY2025). The company funds operations primarily through equity issuances, including at-the-market offerings.

Products and services

Arakoda (tafenoquine) is the primary commercial product, a malaria prevention drug with registered trademarks in Australia, Canada, China, the European Union, Israel, New Zealand, and the Russian Federation. Kodatef is a separately trademarked product with registrations in the same jurisdictions. The company is also conducting a clinical trial of tafenoquine for babesiosis, with direct trial-related costs representing 71% of total R&D costs ($1,496,148) in FY2025. Earlier-stage pipeline includes SJ733 combined with tafenoquine and castanospermine.

Customers and end markets

End markets include malaria prevention and, in clinical development, babesiosis treatment. The company receives grant funding from USAMMDA (U.S. Army Medical Materiel Development Activity), indicating a government and military health customer base alongside commercial channels. No specific commercial customer concentration data is disclosed in the filing excerpts.

Value-chain role

Drug developer and commercial-stage specialty pharmaceutical company. Handles drug development, clinical trials, regulatory IP protection, and direct product commercialization. Outsources synthesis and research functions to third parties including Kentucky Technology, Inc. and Trevally.

Geographic exposure

Trademark registrations across Australia, Canada, China, the European Union, Israel, New Zealand, and the Russian Federation indicate intended multi-jurisdictional commercial presence. The company is incorporated in Delaware. No geographic revenue breakdown is disclosed in the filing excerpts.

Source: SEC 10-K, filed 2026-03-30

Industry: Pharmaceutical Preparations Peers: DMK PHARMACEUTICALS Corp Avenue Therapeutics Inc CNS Pharmaceuticals Inc Eli Lilly and Co Eloxx Pharmaceuticals Inc Processa Pharmaceuticals Inc Hoth Therapeutics Inc Kuvatris Therapeutics, Inc. Pulmatrix Inc Virpax Pharmaceuticals, Inc.